Uroporphyria caused by ethanol in Hfe(-/-) mice as a model for porphyria cutanea tarda

Hepatology

Volumn 37, Issue 2, 2003, Pages 351-358

  Sinclair, Peter R ^a,b   Gorman, Nadia ^a,b   Trask, Heidi W ^a,b   Bement, William J ^a   Szakacs, Juliana G ^c   Elder, George H ^d   Balestra, Dominic ^a,b   Sinclair, Jacqueline F ^a,b   Gerhard, Glenn S ^a,b  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINOLEVULINATE SYNTHASE; ALCOHOL; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 C282Y; HFE PROTEIN; IRON; UNCLASSIFIED DRUG; UROPORPHYRIN; UROPORPHYRINOGEN; UROPORPHYRINOGEN DECARBOXYLASE;

ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; HOMOZYGOSITY; IRON METABOLISM; KNOCKOUT MOUSE; LIVER HOMOGENATE; LIVER INJURY; LIVER METABOLISM; LIVER PARENCHYMA; MOUSE; NONHUMAN; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL;

EID: 0037309599     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50034     Document Type: Article

References (50)

1. Elder GH. Porphyria cutanea tarda. Semin Liver Dis 1998;18:67-76.
2. Elder GH. Alcohol intake and porphyria cutanea tarda. HEPATOLOGY 1998;27:289-291.
3. Elder GH. Porphyria cutanea tarda and related disorders. In: Kadish KM, Smith KM, Guilard R, eds. The Porphyrin Handbook II, Volume 14. Boston: Academic Press, 2003:62-97.
4. Bulaj ZJ, Phillips JD, Ajioka RS, Franklin MR, Griffen LM, Guinee DJ, Edwards CQ, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000;95:1565-1571.
5. Egger NG, Goeger DE, Payne DA, Miskovsky EP, Weinman SA, Anderson KE. Porphyria cutanea tarda. Multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 2002;47:419-426.
6. Sarkany RP. The management of porphyria cutanea tarda. Clin Exp Dermatol 2001;26:225-232.
7. Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997;349:321-323.
8. Tannapfel A, Stolzel U, Kostler E, Melz S, Richter M, Keim V, Schuppan D, et al. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchows Arch 2001;439:1-5.
9. Brady JJ, Jackson HA, Roberts AG, Morgan RR, Whatley SD, Rowlands GL, Darby C, et al. Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda. J Invest Dermatol 2000;115:868-874.
10. Stuart KA, Busfield F, Jazwinska EC, Gibson P, Butterworth LA, Cooksley WG, Powell LW, et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol 1998;28:404-409.
11. Sampietro M, Piperno A, Lupica L, Arosio C, Vergani A, Corbetta N, Malosio I, et al. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. HEPATOLOGY 1998;27:289-291.
12. Brunt EM, Olynyk JK, Britton RS, Janney CG, Di Bisceglie AM, Bacon BR. Histological evaluation of iron in liver biopsies: relationship to HFE mutations. Am J Gastroenterol 2001;95:1788-1793.
13. Smith A, Francis J. Synergism of iron and hexachlorobenzene inhibits hepatic uroporphyrinogen decarboxylase in inbred mice. Biochem J 1983;214:909-913.
14. Sweeney GD, Jones KG, Cole FM, Basford D, Krestynski F. Iron deficiency prevents liver toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Science 1979;204:332-335.
15. Smith AG, Francis JE. Genetic variation of iron-induced uroporphyria in mice. Biochem J 1993;291:29-35.
16. Sinclair PR, Gorman N, Walton HS, Bement WJ, Sinclair JF, Gerhard GS, Szakacs JG, et al. Uroporphyria in Hfe mutant mice given 5-aminolevulinate: a new model of Fe-mediated porphyria cutanea tarda. HEPATOLOGY 2001;33:406-412.
17. Levy JE, Montross LK, Cohen DE, Fleming MD, Andrews NC. The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. Blood 1999;94:9-11.
18. Phillips JD, Jackson LK, Bunting M, Franklin MR, Thomas KR, Levy JE, Andrews NC, et al. A mouse model of familial porphyria cutanea tarda. Proc Natl Acad Sci U S A 2001;98:259-264.
19. Shanley BC, Zail SS, Joubert SM. Effect of ethanol on liver δ-aminolevulinate synthetase in rats. Lancet 1968;1:70-77.
20. Bonkowsky HL, Healey JF, Sinclair PR, Sinclair JF, Pomeroy JS. Iron and the liver. Acute and long-term effects of iron-loading on hepatic haem metabolism. Biochem J 1981;196:57-64.
21. Whitfield JB, Zhu G, Heath AC, Powell LW, Martin NG. Effects of alcohol consumption on indices of iron stores and of iron stores on alcohol intake markers. Alcohol Clin Exp Res 2001;25:1037-1045.
22. Shanley BC, Zail SS, Joubert SM. Porphyrin metabolism in experimental hepatic siderosis in the rat. Br J Haematol 1970;18:79-87.
23. Teschke R, Gorys-Konemann C, Daldrup T, Goerz G. Influence of chronic alcohol consumption on hepatic heme and porphyrin metabolism. Biochem Pharmacol 1987;36:1133-1138.
24. Lambrecht RW, Jacobs JM, Sinclair PR, Sinclair JF. Inhibition of uroporphyrinogen decarboxylase activity. The role of cytochrome P450-mediated uroporphyrinogen oxidation. Biochem J 1990;269:437-441.
25. Sinclair PR, Gorman N, Jacobs JM. Measurement of heme concentration. In: Maines MD, Costa LG, Reed DJ, Sassa S, Sipes IG, eds. Current Protocols in Toxicology. Volume 1. New York: Wiley, 2000:8.3.1-8.3.7.
26. Sinclair PR, Gorman N, Watton HS, Bement WJ, Dalton TP, Sinclair JF, Smith AG, et al. CYP1A2 is essential in murine uroporphyria caused by hexachtorobenzene and iron. Toxicol Appl Pharmacol 2000;162:60-67.
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
28. Sinclair PR, Gorman N, Walton HS, Sinclair JF, Lee CA, Rifkind AB. Identification of CYP1A5 as the CYP1A enzyme mainly responsible for uroporphyrinogen oxidation induced by Ah receptor ligands in chicken liver and kidney. Drug Metab Dispos 1997;25:779-783.
29. Sinclair PR, Gorman N, Cornell NW. Measurement of ALA synthase activity. In: Maines MD, Costa LG, Reed DJ, Sassa S, Sipes LG, eds. Current Protocols in Toxicology. Volume 1. New York: Wiley, 1999: 8.2.1-8.2.11.
30. d SWR mice. Biochem Pharmacol 1983;52:1407-1413.
31. Gorman N, Walton HS, Bement WJ, Honsinger CP, Szakacs JG, Sinclair JF, Sinclair PR. Role of small differences in CYP1A2 in the development of uroporphyria produced by iron and 5-aminolevulinate in C57BL/6 and SWR strains of mice. Biochem Pharmacol 1999;58:375-382.
32. Sinclair PR, Gorman N, Dalton T, Walton HS, Bement WJ, Sinclair JF, Smith AG, et al. Uroporphyria produced in mice by iron and 5-aminolaevulinic acid does not occur in Cyp1a2(-/-) null mutant mice. Biochem J 1998;330:149-153.
33. Smith AG, Clothier B, Carthew P, Childs NL, Sinclair PR, Nebert DW, Dalton TP. Protection of the Cyp1a2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 2001;173:89-98.
34. Gorman N, Ross KL, Walton HS, Bement WJ, Szakacs JG, Gerhard GS, Dalton TP, et al. Uroporphyria in mice: thresholds for hepatic CYP1A2 and iron. HEPATOLOGY 2002;35:912-921.
35. Louis CA, Wood SG, Kostrubsky V, Sinclair PR, Sinclair JF. Synergistic increases in rat hepatic cytochrome P450s by ethanol and isopentanol. J Pharmacol Exp Ther 1994;269:838-845.
36. Hall P de la M, Lieber CS, DeCarli LM, French SW, Lindros KO, Jarvelainen H, Bode C, et al. Models of alcoholic liver disease in rodents: a critical evaluation. Alcohol Clin Exp Res 2001;25:254S-261S.
37. Bowers BJ, Owen EH, Collins AC, Abeliovich A, Tonegawa S, Wehner JM. Decreased ethanol sensitivity and tolerance development in gammaprotein kinase C null mutant mice is dependent on genetic background. Alcohol Clin Exp Res 1999;23:387-397.
38. Shanley BC, Zail SS, Joubert SM. Effect of ethanol on liver deltaaminolaevulinate synthetase activity and urinary porphyrin excretion in symptomatic porphyria. Br J Haematol 1969;17:389-396.
39. Smith AG. Porphyria caused by chlorinated AH receptor ligands and associated mechanisms of liver injury and cancer. In: Kadish KM, Smith KM, Guilard R, eds. The Porphyrin Handbook II. Volume 14. Boston: Academic Press, 2003:169-210.
40. Urquhart J, Elder GH, Roberts AG, Lambrecht RW, Sinclair PR, Bement WJ, Gorman N, et al. Uroporphyria produced in mice by 20-methylcholanthrene and 5-aminolaevulinic acid. Biochem J 1988;252:357-362.
41. Brissot P, Wright TL, Ma WL, Weisiger RA. Efficient clearance of nontransferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest 1985;76:1463-1470.
42. McKie AT, Barow D, Latunde-Dada GO, Rolfs A, Sager G, Mudaly E, Mudaly M, et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 2001;291:1755-1759.
43. Fleming RE, Sly WS. Mechanisms of iron accumulation in hereditary hemochromatosis. Annu Rev Physiol 2002;64:663-680.
44. Cederbaum A. Introduction-serial review: alcohol, oxidative stress and cell injury. Free Radic Biol Med 2001;31:1524-1526.
45. Sinclair PR, Gorman N, Walton HS, Bement WJ, Szakacs J, Gonzalez FJ, Dalton TP, et al. Relative roles of CYP2E1 and CYP1A2 in mouse uroporphyria caused by acetone. Arch Biochem Biophys 2000;384:383-390.
46. Bulaj ZJ, Franklin MR, Phillips JD, Miller KL, Bergonia HA, Ajioka RS, Griffen LM, et al. Transdermal estrogen replacement therapy in postmenopausal women previously treated for porphyria cutanea tarda. J Lab Clin Med 2000;136:482-488.
47. Sinclair PR, Gorman N, Tsyrlov IB, Fuhr U, Walton HS, Sinclair JF. Uroporphyrinogen oxidation catalyzed by human cytochromes P450. Drug Metab Dispos 1998;26:1019-1025.
48. Jackson HA, Carter K, Darke C, Guttridge MG, Ravine D, Hutton RD, Napier JA, et al. HFE mutations, iron deficiency and overload in 10,500 blood donors. Br J Haematol 2001;114:474-484.
49. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002;122:281-289.
50. Bonkovsky HL, Lambrecht RW. Iron-induced liver injury. Clin Liver Dis 2000;4:409-429.